MedPath

INVOX PHARMA LIMITED

🇬🇧United Kingdom
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

7

Active:4
Completed:1

Trial Phases

1 Phases

Phase 1:7

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 1
7 (100.0%)

FS222 First in Human Study in Patients With Advanced Malignancies

Phase 1
Recruiting
Conditions
Advanced Cancer
Metastatic Cancer
Interventions
First Posted Date
2021-02-05
Last Posted Date
2025-07-01
Lead Sponsor
invoX Pharma Limited
Target Recruit Count
260
Registration Number
NCT04740424
Locations
🇦🇺

Calvary Mater Newcastle, Waratah, New South Wales, Australia

🇦🇺

One Clinical Research Perth, Perth, Western Australia, Australia

🇬🇪

Arensia Exploratory Medicine, LLC, Tbilisi, Georgia

and more 18 locations

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

Phase 1
Active, not recruiting
Conditions
Metastatic Cancer
Advanced Cancer
Interventions
First Posted Date
2020-12-01
Last Posted Date
2025-06-27
Lead Sponsor
invoX Pharma Limited
Target Recruit Count
82
Registration Number
NCT04648202
Locations
🇺🇸

Yale University, New Haven, Connecticut, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States

and more 6 locations

Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Head and Neck Squamous Cell Carcinoma
Melanoma
Solid Tumor
Interventions
First Posted Date
2019-09-20
Last Posted Date
2024-10-31
Lead Sponsor
invoX Pharma Limited
Target Recruit Count
61
Registration Number
NCT04096638
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies

Phase 1
Terminated
Conditions
Advanced Cancer
Metastatic Cancer
Squamous Cell Carcinoma of Head and Neck
Interventions
First Posted Date
2018-02-22
Last Posted Date
2025-07-01
Lead Sponsor
invoX Pharma Limited
Target Recruit Count
80
Registration Number
NCT03440437
Locations
🇺🇸

University of California Los Angeles (UCLA), Los Angeles, California, United States

🇺🇸

Yale University School of Medicine, New Haven, Connecticut, United States

🇺🇸

Emory Healthcare, Atlanta, Georgia, United States

and more 9 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.